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1.
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's or Charcot disease, is a late-onset fatal motor neuron progressive disorder that leads to muscle deterioration and paralysis. The incidence of ALS is around two to three people per year out of 100,000 of the general population , being classified as a rare disease .
However, ALS is the third prevalent neurodegenerative disease, affecting 150 ,000 people in the world [1] .
The rate at which ALS progresses can vary from one person to another. Although the mean survival time is three to five years, many patients can live over five to ten years and even over ten . Sporadic ALS (90-95%) constitutes the large majority of cases, while the remaining 5-10% of the patients are affected by the hereditary form termed familial ALS. Both sporadic and familial ALS are associated with cortical and spinal motor neuron degeneration [2] . The etiology of ALS remains unknown and the exact mechanisms of ALS pathogenesis are not fully understood yet . However some pathological pathways comprising of glutamate excitotoxicity, oxidative stress, microglia activation, ion channel and mitochondria dysfunction, apoptosis and different proteinopathies are signatures of this disorder [3] . To this date, ALS is not a curable disease and does not have an effective treatment . Current treatment regimens are largely only focused on relieving symptoms to improve the quality of life of those affected [4] .
Riluzole remains the only approved therapy available for patients with ALS and shows a very modest efficiency on decelerating the progression of the disease , being more effective in early affected patients [5] . Although it is recognize d to decrease the neurotoxic effect of glutamate [6] , its mechanism of action remains largely unknown and the efficiency of drugs is needed urgently by both patients and their families .
Different obstacles prevent the progress and translation of new drugs from the bench to the patients, being the lack of suitable animal models one of them [7] . Although some of them mimic several aspects of the disease, no animal model fully replicates the spectrum of phenotypes encountered in the human disease, making it difficult to assess how a therapeutic effect observed in disease models could predict the efficacy in humans. Importantly, the genetic and phenotypic heterogeneity of ALS leads to a variety of responses to similar treatment regimens [8] . However, r ecent knowledge in the molecular pathways behind ALS together with new trends in clinical trial design s has provided hope for effective therapies in the future [9, 10] .
This review tries to summarize current drugs and/or therapies in clinical trials for ALS, Here, Table 1 New ALS biomarkers in clinical studies 2.
Currently there is a lack of useful biomarkers in ALS. This cause s a diagnostic delay among other issues, from the time of first symptoms to first medical consultation or initial evaluation of more common disorders [11] , and the impossibility of proper patient classification in order to identify those that may respond better to a particular drug. For this reason multiple drugs have failed for ALS treatment as they have been administered in the late stages of the disease. Although today the diagnosis is based on the opinion of an experienced neurologist assessment and on electromyogram investigation with accepted criteria, in the last decade there has been a huge interest in discovering biomarkers for this disease.
A biomarker is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathologic processes, or biological response to a therapeutic intervention" [12] .
Today different biomarkers ha ve emerged such as biological fluid-based (e.g. CSF superoxide dismutase 1 levels, phosphorylated neurofilament light chain, urinary p75NTR ECD ), neuroimaging techniques (e.g. magnetic resonance imaging, positron emission tomography) and electrophysiological parameters (e.g. electrical impedance myography) among others [13] .
In the following paragraphs, we will report the different clinical studies aimed to identify and/or validate biomarkers ongoing for ALS (Table 2) .
Flutriciclamide (
18
F-GE-180) is a recently developed third generation 18 kDa
translocator protein (TSPO) used as in vivo marker of neuroinflammation [14] . The TSPO receptor, also called the peripheral benzodiazepine receptor (PBR), is one of the most studied biomarkers of neuroinflammation [15, 16] . Here, Table 2 Cell therapies 3.
Given the great need for an effective ALS therapy some alternative approaches to small molecules such as cell therapies are being studied . Stem cell therapy offers a In the attempt of finding other non-neuronal cells that could be transplanted to ALS patients and provide clinical benefit human glial restricted progenitor cells have been studied. These direct interventions show neuroprotection in mice however more studies are needed to establish whether they could contribute to a clinical benefit in patients
When the use of stem cells is considered as a new treatment, the complexity of the clinical trial design is increased due to heterogeneity of these cells, limited knowledge about optimal dosing or way of delivery among other issues. All these points were Here, Table 3 Biological drugs for ALS 4. 
Drug repurposing 5.
Finding new uses for existing drugs, the so called drug repurposing strategy is a fruitful method to discover and develop new drugs for rare diseases. Several approved drugs for many different medical needs are currently in clinical development for ALS (Figures   1 and 2 ). 
Triumeq®. This antiretroviral, an HIV medication, is now investigated in a phase IIa
T amoxifen.
After the serendipitous finding that ALS patients with breast cancer treated with tamoxifen seemed to improve neurologically, and that it was somehow responsible for reducing the rate of progression [45] , preliminary evidences suggested that tamoxifen might be neuroprotective in stroke and hypoxia [46] . This drug is an estrogen-receptor modulator (SERM), but its neuroprotective action looks to be related to its ability to inhibit protein kinase C, which is increased in the spinal cord of ALS patients [47] . More recently, tamoxifen has been discovered as an autophagy modulator being able to modulate the main proteinopathy present in ALS, the TAR DNAbinding protein 43, in animal models [48] . Based on th ese findings, a phase II study in ALS patients treated with riluzole and also with tamoxifen was started in 2014 sponsored by Taipei Medical University Shuang Ho Hospital (Taiwan), although no updates have been posted (Clinicaltrial.gov NCT02166944).
Mexiletine.
Motor neuron hyperexcitability appears to be linked to the process of neurodegeneration in ALS. As such, therapies that inhibit neuronal hyperexcitability may prove effective in arresting the progression of ALS [49] . That is the case of t he antiarrhythmic drug Mexiletine, a sodium channel blocker. It was used in a phase II double-blind randomized controlled trial of sporadic ALS, sponsored by the University of Washington (USA), to determine safety and tolerability due to its ability to reduce hyperexcitability, a potential early step in the disease (Clinicaltrial.gov NCT01849770).
The drug was safe when given daily to ALS patients at 300 and 900 mg and welltolerated at the lower dose. The treatment resulted in large dose-dependent reductions in muscle cramp frequency and severity. No effect on r ate of progression was detected although clinically important differences may not be excluded due to the short-duration of the study [50]. that the drug has potential to be a treatment option for mild to moderate AD, and all adverse reactions were mild [58] . CTG is a highly attractive candidate for the treatment of neurodegenerative conditions such as ALS and a clinical trial to assess its clinical response is being sponsored by University of Pekin (Clinicaltrial.gov NCT00753571).
Ezogabine
However, data is not available at the moment. Here, Figure 2 New drugs for ALS under clinical development 6.
Masitinib, is a tyrosine-kinase inhibitor marketed by AB
The urgent need of finding a cure for ALS has pressured different academic and private laboratories to start drug discovery programs directed to modulate this fatal pathology despite its unknown etiology or the lack of good cellular or animal models that mimic the disease [65, 66] . As a result, currently there are several new investigational drugs in clinical trials for ALS (Figure 3 ).
Tirasemtiv.
Although the regulation of muscle contraction by the troponin complex is well known [67] , only in the last few years it was discovered that t roponin activation may provide a new therapeutic approach to improve physical activity in diseases where neuromuscular function is compromised [68] . In that way, the small molecule CK-2017357 also known as Tirasemtiv, a fast-skeletal-troponin activator, is able to increase muscle strength and performance in mice modulating the rate of calcium release from troponin C [69] . Moreover, and after showing to be safe and tolerable in ALS patients [70] , Tirasemtiv has shown the potential to amplify the skeletal muscle response in humans [71] . Recently, it has received the orphan drug designation and 6.2 Arimoclomol, a small molecule discovered initially by Hungarian researchers as a drug candidate to treat insulin resistance and diabetic complications [72] , has recently shown to reduce protein aggregates levels in motor nerves . This new investigational drug candidate is able to increase the expression of chaperons Hsp70 and Hsp90 which help newly synthesized proteins fold properly [73] . Arimoclomol has also shown beneficial effects in muscle denervation in the SOD transgenic ALS mice [74] , and is being tested in a Phase II/III study to determine tolerability and efficacy in subjects with SOD1 positive familial ALS sponsored by the University of Miami (USA) (Clinicaltrial.gov NCT00706147). Previously, arimoclomol showed to be well tolerated in ALS patients [75] . Results from the ongoing study are expected by the end of the year and will indicate if arimoclomol could become a disease modifiying drug for this familial subgroup of patients.
6.3 RNS60. This novel therapeutic is an electrokinetically altered aqueous fluid composed of 0.9% saline containing charge-stabilized oxygen nanobubble-based structures. Chemically, RNS60 contains water, sodium chloride, and 55±5ppm oxygen.
Despite the absence of active pharmaceutical ingredients, RNS60 has proven to be antiinflammatory and neuroprotective in different models [76] [77] [78] , being proposed as a new therapeutic option for neuroinflammatory and neurodegenerative disorders [79] .
Furthermore, RNS60 has shown some benefit in myelin maintenance and repair [80] .
Sponsored by Revalesio, a Phase I clinical study to determine safety and tolerability in ALS patients has been initiated with RNS60 administered by intravenous and inhalation routes (Clinicaltrial.gov NCT02525471). The study is recruiting ALS volunteers and the completion of the study is estimated by the end of 2017. shown [84] , the use of Cu(II)ATSM may attenuate disease symptoms and prolong survival in sporadic ALS patients as it was observed in SOD1 animal models.
6.5 NP001. Based on the relationship between ALS progression and neuroinflammation [85] , NP001, a small heterocyclic molecule regulator of inflammatory macrophages and monocytes, was included in a phase I study in patients with ALS showing to be safe and tolerable [86] . Afterwards, a Phase II to assess preliminary efficacy of NP001 in ALS patients was conducted [87] , presenting a decreas e of disease progression in a small subset of patients which motivated Neuraltus Pharmaceuticals (USA) to start a second Phase II clinical study to confirm this data (Clinicaltrial.gov NCT02794857). The recruitment is currently open.
6.6 EPI-589.The small molecule EPI-589, also named as (R)-troloxamide quinone, has started clinical development. Although there is no data available about the efficacy of this antioxidant drug in ALS animal models , Edison Pharmaceutical initiated a Phase IIA safety and biomarker study of EPI-589 in ALS patients . As the new drug candidate acts through a redox-based mechanism, the secondary outcome of the study will be the potential impact of the compound on the levels of glutathione in blood samples from participants (Clinicaltrial.gov NCT02460679).
GDC-0134. Finally, GDC-0134 is an inhibitor of Dual Leucine Zipper Kinase (DLK)
being developed by Genentech. A clinical trial phase I is currently recruiting participants in a single ascending-dose study to determine the safety, tolerability and some pharmacokinetic parameters. DLK regulates neuronal regeneration and it was recently shown that its inhibition promotes neuroprotection, preventing axon degeneration [88] , which could be of great benefit to treat ALS patients.
Here, Figure 3 
Conclusions
7.
Finding a cure for ALS is one of the great est challenges for those working in central nervous system drug discovery. Not only for the severity of the disease and the great social need, but also for the lack of validated targets and animal models. However, thanks to recent public and private research and development effort s, we have currently several clinical trials ongoing to fight against ALS.
Some studies are focused on the development of imaging-agents that will allow for a better diagnostic and disease follow-up in the next future, being the development of MRI/PET agents the most advanced one. Other clinical trials are focused in cell therapy strategies. There are several studies ongoing , but up to date there is a lack of highquality evidence to guide practice on the use of cell-based therapy to treat ALS [89] .
Important key points such as the determination of the appropriate cell source, 
Expert Opinion 8.
ALS is a fatal and devastating neurodegenerative disease for which no treatment exists. This terrible deficiency may be due to a number of factors.
The first historical one may be found in the number of patients affected by the disease. ALS is a rare disease and , based exclusively in economic criteria , little research has been done by pharma companies until the last years/decades in th is kind of pathologies. In fact, it has been the public claims coming from patient associations that have recently impacted favorably on investment decisions and research on rare diseases is currently one of the preferred fields for many companies. ALS patient´s associations are very active and believe in research as the only way to find a cure , investing resources and leading an important opinion to guide investments coming from public and private sectors.
A second important point is the lack of good animal models able to mimic the disease.
Since the ninety 's decade no models w ere available, and after , different transgenic mice were developed based only in different mutations of SOD-1. Finding some signs of efficacy in those mice after treatment with different molecules was not significantly difficult. H owever, the translation of the preclinical results to the clinic has been unsuccessful every time. Currently, after some years of basic and applied research, it is known that SOD-1 mutations are present only in less than 10% of familiar ALS cases which represents a small fraction of the overall disease. Differ ent strategies are being follow ed now to improve translational research success [7] , being personalized medicine a new opportunity for genetic patients. Furthermore, as the knowledge of the pathobiology of ALS advance s, investigators are focusing on concepts that had not been examined previously and new animal models are being developed to provide innovative future possibilities for drug discovery [90] . of these factors, joined to new criteria for clinical trial designs [8] , leads us to believe that f uture research will find the best approach to prevent or reverse the neurological deficit in ALS, and prolong survival rates in this debilitating and fatal condition. 
